Navigation Links
Combo of Avastin, second drug shows promise fighting brain cancer, Mayo Clinic finds
Date:2/14/2013

JACKSONVILLE, Fla. The drug bevacizumab, also known by the trade name Avastin, shrinks tumors briefly in patients with an aggressive brain cancer known as glioblastoma multiforme, but then they often grow again and spread throughout the brain for reasons no one previously has understood. Now, Mayo Clinic researchers have found out why this happens. They have also discovered that pairing Avastin with another cancer drug, dasatinib, can stop that lethal spread. Dasatinib is approved for use in several blood cancers.

The findings, based on an animal study, are detailed in the Feb. 14 online issue of PLOS ONE. Based on those results, Mayo Clinic has already conducted a phase I clinical trial testing a combination of bevacizumab and dasatinib in glioblastoma patients whose other therapies failed. Mayo is now carrying out a randomized phase II study of 100 patients through Alliance for Clinical Trials in Oncology, a clinical trials network supported by the National Cancer Institute.

"We are very encouraged. This finding could potentially benefit many cancer patients," says co-author Panos Z. Anastasiadis, Ph.D., chair of the Department of Cancer Biology at Mayo Clinic in Florida. Working with him were researchers and oncologists from Mayo Clinic campuses in Florida and Minnesota.

The research began after Dr. Anastasiadis, a basic scientist who studies cell adhesion and migration, gave a seminar to a group of oncologists who treat brain tumors. The issue of bevacizumab-induced invasion was brought up and a collaboration to study it was quickly set up and funded by the Mayo Clinic Specialized Program of Research Excellence (SPORE) grant for brain cancer, one of only four in the country.

The issue of bevacizumab's induced aggressiveness is not limited to brain cancer, Dr. Anastasiadis says.

"While Avastin offers clear benefit in some patients, oncologists have noted that when cancers of many types recur after use of Avastin, they become aggressive and invasive," he says.

The team discovered that as brain tumors become more aggressive after use of bevacizumab in mice, the cancers begin inducing a family of kinases known as Src, which then activate proteins found at the edge of brain tumors. These proteins essentially give the tumor cells "legs" upon which to crawl away and find a new source of nutrition, Dr. Anastasiadis says.

"Anti-angiogenesis drugs like Avastin deprive tumor cells of blood nutrients, so the tumors shrink initially, but we believe that this deprivation acts like a switch to turn on proteins that help the cancer cells migrate to other parts of the brain in search of blood," he says. "In short, if Avastin does not allow a tumor to make new blood vessels to feed it, the tumor will move to other existing blood vessels."

The researchers then tested dasatinib, a drug that inhibits Src kinases. They found that while use of bevacizumab or dasatinib alone did not provide much benefit in mouse models of human glioblastoma, use of both together shrank tumors and blocked any subsequent spread.

"If you block that migration, the cells are forced to stick together and hopefully die by lack of nutrition," Dr. Anastasiadis says.

Researchers next will work to identify which patients benefit the most from this new treatment, which do not, and why.


'/>"/>

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. New screening approach identified potential drug combos for difficult-to-treat melanomas
2. Combo Therapy May Help Ease Sleep Apnea at High Altitude
3. HIV Drug Combo May Help Prevent Malaria Reinfection
4. Being neurotic, and conscientious, a good combo for health
5. PI3-kinase and PARP inhibitor combo may offer new treatment option for triple-neg breast cancers
6. Cooking-Oil Combo May Improve Blood Pressure
7. Double drug combo could shut down abnormal blood vessel growth that feeds disease
8. Drug combo better for common type of metastatic breast cancer, UCI-led study finds
9. Booze, Energy Drinks, Casual Sex Combo Common in College: Study
10. FDA Approves Combo Shot for Meningitis, Hib in Kids
11. Combo Therapy May Help Ease Ringing in the Ears
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... Carlos ... problems. He has also continued to spiritually evolve, which is the purpose of everyone ... “ Our Spiritual Truths ” (published by Balboa Press) attempts to guide readers to ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... athletics. It’s enough to overwork even the sharpest brain. , Power On, a ... healthy activity without over clocking the brain. Each capsule contains Cognizin® Citicoline, a ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... medicine in recent years. The technology is so cutting edge, in fact, the ... protocol for stem cell procedures. However, successful patient outcomes in certain clinical stem ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... services to the largest network of hospitals, health information exchanges, physicians and patients, ... Health Information Technology (ONC-HIT) 2015 Edition Health IT Module Certification via Drummond Group ...
(Date:2/22/2017)... ... , ... South Bend’s Lunkerville, the award-winning TV series that catches real people ... (HOW), a non-profit organization dedicated to helping military veterans relax, rehabilitate, and reintegrate through ... to Lake Denmark, New Jersey, to fish with war veteran Justin Vail from the ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), today announced ... ended December 31, 2016. ... This news release should be read ... discussion and analysis for the years ended December 31, 2016 ... available at www.sedar.com and on the Company,s website ...
(Date:2/22/2017)... LONDON , Feb. 22, 2017 astic ... new type of antineoplastic drug aiming at functions at ... stepped in to a new stage. Download ... now, there are nearly four million cases of new ... With aging of population, environmental pollution caused by industrialization ...
(Date:2/22/2017)... NEW YORK , Feb. 22, 2017 /PRNewswire/ ... to the congestive heart failure partnering deals and ... companies. Read the full report: http://www.reportlinker.com/p03605673-summary/view-report.html ... Partnering since 2010 report provides understanding and access ... the world,s leading healthcare companies. - ...
Breaking Medicine Technology: